Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Christopher Liu is an analyst at Leerink Partners. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 04/07/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 12/04/2024 | RLAY | Buy Now | Relay Therapeutics | $2.09 | 761.2% | Christopher Liu44% | $19 → $18 | Maintains | Outperform | Get Alert |
| 11/05/2024 | IDYA | Buy Now | IDEAYA Biosciences | $15.14 | 78.34% | Christopher Liu44% | $41 → $27 | Downgrade | Outperform → Market Perform | Get Alert |
| 08/08/2023 | NUVL | Buy Now | Nuvalent | $64.68 | -35.06% | Christopher Liu44% | → $42 | Initiates | → Market Perform | Get Alert |
| 08/08/2023 | IDYA | Buy Now | IDEAYA Biosciences | $15.14 | 117.97% | Christopher Liu44% | → $33 | Initiates | → Outperform | Get Alert |
| 08/08/2023 | EXEL | Buy Now | Exelixis | $35.00 | -48.57% | Christopher Liu44% | → $18 | Initiates | → Market Perform | Get Alert |
